Sign In

Jens Eckstein

Biotech Founder and Investor

Jens Eckstein is a prominent figure in the life sciences and biopharma sectors, currently serving as a member of the Board of Directors at Vandria SA, a company focused on developing innovative therapeutics targeting age-related and chronic diseases through mitophagy inducers. His involvement with Vandria follows his recent appointment as an Investment Partner at the Hevolution Foundation, where he focuses on supporting healthy aging initiatives.

Professional Background

Eckstein has over 18 years of experience in biopharma venture capital and company creation, along with a decade of operational experience in drug discovery and development. Notably, he previously held the position of President at GlaxoSmithKline’s corporate venture fund, SR One, where he oversaw investments exceeding $500 million and was involved in numerous IPOs and M&A transactions.12

In addition to his role at Vandria, Eckstein is actively engaged in various advisory positions, including:

  • Member of the Board of Advisors at Apollo Health Ventures
  • President of Galilei Biosciences
  • Advisor to multiple biotech companies such as Booster Therapeutics and Refoxy Pharma.1

Contributions to Vandria SA

Eckstein joined Vandria's board in August 2024 as part of a financing round that raised a total of CHF 30.7 million (approximately $33 million) for the company. His expertise is expected to significantly contribute to Vandria's mission to advance its lead compound, VNA-318, which is aimed at treating neurodegenerative diseases like Alzheimer's and Parkinson's.34

Education and Mentorship

He is also recognized as a Kauffman Fellow and serves on the EU-sponsored Gold Track Expert Council. Eckstein is passionate about mentoring entrepreneurs and start-up teams within the life sciences sector, further emphasizing his commitment to fostering innovation in healthcare.21

Language Proficiency

Eckstein is multilingual, with proficiency in English (native), German (native), and limited working proficiency in French.1

Overall, Jens Eckstein's extensive background in venture capital, combined with his leadership roles in various biotech ventures, positions him as a key player in advancing therapeutic solutions for aging-related health challenges.

Highlights

Aug 21 · hevolution.com
Vandria's lead CNS compound VNA-318 is a mitophagy inducer ...
Aug 21 · startupticker.ch
Over CHF 14M secured to support Vandria's momentum
Aug 21 · globenewswire.com
Hevolution Foundation and Dolby Family Ventures join

Related Questions

What are Jens Eckstein's main responsibilities at Vandria SA?
How has Jens Eckstein's experience at Hevolution Foundation influenced his role at Vandria SA?
What are some of the notable projects Jens Eckstein has been involved in at Apollo Health Ventures?
How does Jens Eckstein's background in biopharma venture capital benefit Vandria SA?
What is the significance of Jens Eckstein's role as a Kauffman Fellow?
Jens Eckstein
Jens Eckstein, photo 1
Jens Eckstein, photo 2
Add to my network

Location

Cambridge, Massachusetts, United States